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The diagnosis of progressive disseminated histoplasmosis is often a challenge to clinicians,
especially due to the low sensitivity and long turnaround time of the classic diagnostic meth-
ods.  In recent years, studies involving a variety of non-culture-based diagnostic tests have
been  published in the literature. We  performed a systematic review by selecting studies eval-
uating non-culture-based diagnostic methods for progressive disseminated histoplasmosis.
We  searched for articles evaluating detection of antibody, antigens, as well as DNA-based
diagnostic methods. A comprehensive PUBMED, Web of Science, and Cochrane Library
search was performed between the years 1956 and 2016. Case reports, review articles, non-
human models and series involving less than 10 patients were excluded. We  found 278
articles and after initial review 18 articles were included: (12) involved antigen detection
methods, (4) molecular methods, and (2) antibody detection methods. Here we  demonstrate
that the pursuit of new technologies is ultimately required for the early and accurate diag-
nosis of disseminated histoplasmosis. In particular, urinary antigen detection was the mostaccurate tool when compared with other diagnostic techniques.
©  2016 Sociedade Brasileira de Infectologia. Published by Elsevier Editora Ltda. This is an
open  access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/
moist nitrogen-rich soils containing excrement from poul-
try, bats, or birds. Even though histoplasmosis may be antroductionPlease cite this article in press as: Falci DR, et al. Progressive disseminate
culture-based diagnostic tests. Braz J Infect Dis. 2016. http://dx.doi.org/10.
istoplasmosis is a fungal disease caused by the ther-
ally dimorphic fungus Histoplasma capsulatum.1 Humans
evelop histoplasmosis by inhaling H. capsulatum spores
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from the environment, usually in the context of acid andd histoplasmosis: a systematic review on the performance of non-
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self-limiting disease, disseminated infection may occur par-
ticularly in the immunocompromised host. Diagnosis of
lsevier Editora Ltda. This is an open access article under the CC
.
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Databases  search 
(Pubmed /MEDL INE,  Cochra ne 
Library, Web of Science)
Search strategy resulted in 278 articles 
Titles and abstracts reviewed by two independent reviewers 
Arti cles includ ed in  the  revie w (n=18)  
Excluded (n= 260):  
review articles (n=77), 
case report s (n=117),  
non-hum an s tud ies 
(n=26),  n<10  (n=12 ), 
and non-Histo plas ma
stu dies (n=28 ) 
Manuscript rev iew and data e xtract ion 
Fig. 1 – Finding evidence for comparing diagnostic studies
for progressive disseminated histoplasmosis.
progressive disseminated histoplasmosis (PDH) has histor-
ically been made by combination of fungal culture and
histopathology. However, these may require invasive medi-
cal procedures to obtain tissues, and cultures may take up
to six weeks to reveal fungal growth.2,3 Moreover, in recent
years a variety of non-culture-based diagnostic methods have
been developed to diagnose PDH aiming for an early and more
sensitive diagnosis.2 In this study we  performed a system-
atic review of the available data on these novel technologies,
summarizing their performance.
Methods
A computerized search without language restrictions was
conducted in Pubmed/MEDLINE, Web of Science, and
Cochrane Library, for articles published up to June 2016
combining the following terms ((DISSEMINATED HISTOPLAS-
MOSIS) AND (ANTIBODY OR MOLECULAR OR “POLYMERASE
CHAIN REACTION”[MH] OR ANTIGEN OR IMMUNODIFFUSION
OR “COMPLEMENT FIXATION TESTS/METHODS”[MAJR] OR
“LATEX FIXATION TESTS”[MH]) AND (DIAGNOSIS)). Only orig-
inal articles dealing with non-culture-based diagnostic tests
for PDH were studied. References from selected articles were
also screened for review. Publications describing case reports,
review articles, case series involving <10 patients, and histo-
plasmosis in non-humans were not included in the review
(Fig. 1).
This systematic review aimed to summarize the per-
formance of non-culture-based diagnostic methods for the
detection of H. capsulatum, focusing on three distinct test
groups: (i) antibody detection tests, including immunodiffu-Please cite this article in press as: Falci DR, et al. Progressive disseminat
culture-based diagnostic tests. Braz J Infect Dis. 2016. http://dx.doi.org/10.
sion, complement ﬁxation and latex agglutination; (ii) antigen
detection tests, including enzyme immunoassays (EIAs); and
(iii) molecular methods. A total of eighteen studies were
included in the review (Table 1). 6;x x x(x x):xxx–xxx
Results
Serological  tests:  immunodiffusion,  complement  ﬁxation,
and  latex  agglutination  test
Currently, two main serological tests are used for the detection
of H. capsulatum antibodies: immunodiffusion and comple-
ment ﬁxation.2 Although these methods have the advantage
of being non-invasive, but enclose several limitations, includ-
ing (i) marked intra-patients variation in results; (ii) long time
for positive results (up to six weeks are required after expo-
sure for antibody production); (iii) potential cross-reactivity
with antibodies produced by other fungi such as Blastomyces
dermatitidis.1–5
The immunodiffusion method is widely used in clinical
practice and it is based on the precipitation of the anti-M and
anti-H antibodies. This method is more  speciﬁc than the com-
plement ﬁxation2,3 and presents the following strengths: (i)
it is based on simple and reliable methodology; (ii) it has a
low cost; (iii) speciﬁcity is close to 70–100%.2,4 Test sensitivity
is unacceptably low in the immunocompromised population,
particularly in individuals with AIDS.
The complement ﬁxation method is more  sensitive than
the immunodiffusion test and presents variable test sensi-
tivity, depending on the antigen phase, ranging from 72.8%
in mycelial to 94.3% in yeast phase. The speciﬁcity varies
between 70% and 80%; cross-reactions may occur with blas-
tomycosis, candidosis, and paracoccidioidomycosis. Antibody
titers of 1:8 and 1:16 are frequently seen in individuals with
past infections or living in endemic regions and these are con-
sidered weakly positive results. Test sensitivity is reduced in
the presence of hemolytic and lipemic samples.2,3
H. capsulatum may also be detected by the means of latex
agglutination test. The test is based on latex connection
with histoplasmin for the detection of the antibody anti-
Histoplasma. Studies conducted in mid  to late 1970s demon-
strated that the latex test was not well-suited for diagnosis
of PDH due to low sensitivity (64%) and cross-reactivity with
tuberculosis, in a comparison with the gel immunodiffusion.5
Main test advantages are low cost and better speciﬁcity, as
compared to the complement ﬁxation test, despite of false-
positives observed with M. tuberculosis infection.2,5
Immunological  tests:  enzyme  immunoassays  (EIAs)
EIAs are based on the detection of the H. capsulatum polysac-
charide antigen (HPA) on various biological materials such
as urine, serum, and bronchoalveolar washing ﬂuid. Differ-
ent EIAs have been used as surrogate of PDH by reference
laboratories.6–9 Two commercial EIA tests to detect H. capsu-
latum are currently available in the United States of America:
MVista in Indianapolis, IN, and IMMY in Norman, OK. Both
laboratories provide similar and robust EIA tests with minor
differences in terms of test performance. However, there has
been a strong debate in the literature on difference betweened histoplasmosis: a systematic review on the performance of non-
1016/j.bjid.2016.09.012
them, which seems to be inﬂuenced by a marked commercial
bias.8,10–13
In 1989, Wheat and other researchers from Miravista Diag-
nostics (Indianapolis, IN) developed a rapid and promising
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Table 1 – Studies included in the systematic review.
Reference Method n Population studied Main results
Arango-Bustamante
et al., 2013
Serology (CF and ID) 391 HIV and non-HIV, PDH
patients
Positivity non-HIV: CF 87%,
ID 95%; HIV: CF 79%, ID 92%
Gerber et al., 1972 Serology (CF and LA) 70 Acute, chronic pulmonary
and PDH, individuals
without histoplasmosis
Positivity: Acute, LA: 97%,
CF: 91%. Chronic, LA: 96%,
CF: 91%. PDH, LA: 64%, CF:
82%
Gutierrez et al., 2008 Antigen detection (MVista
®
EIA)
21  AIDS patients with PDH Sensitivity: Panamanian
patients, 95.2%; US
patients, 100%
Cloud et al., 2007 Antigen detection (IMMY
®
EIA and MVista
®
EIA)
99 Random urine samples
from reference laboratory
Agreement for positive
samples: 92%
Negative samples: 98%
Scheel et al., 2009 Antigen detection (ELISA
developed by CDC)
217  AIDS patients from
Guatemala
Sensitivity: 81%; speciﬁcity:
95%
Theel et al., 2013 Antigen detection
(comparison between
IMMY
®
EIA and MVista
®
EIA)
1003 Random urine samples Overall agreement of 97.6%
Connolly et. al., 2007 Antigen detection (MVista
®
EIA 2nd generation)
130  PDH patients and controls Sensitivity: 100%;
speciﬁcity: 99%
Zimmerman et al., 1989 Antigen detection
(comparison between
AP-ELISA, HRP-ELISA and
RIA)
19 PDH AP- and HRP-ELISA: 89.5%
positivity; RIA: 94.7%
positivity
Wheat et al., 1989 Antigen detection
(HPA-ELISA)
61 PDH, AIDS patients Positivity, urine: 96.7%;
blood: 78.7%
Durkin et al., 1997 Antigen detection
(comparison between RIA
and EIA)
182  PDH patients and controls Correlation coefﬁcient:
0.974
LeMonte et al., 2007 Antigen detection
(comparison between
IMMY
®
EIA and MVista
®
EIA)
50  PDH patients and controls Sensitivity for IMMY
®
: 44%;
speciﬁcity: 84% for IMMY
®
,
98% for MVista
®
Gomez et al., 1997 Antigen detection (MAb
ELISA)
35  PDH in AIDS and non-AIDS
patients, acute and chronic
histoplasmosis
Overall sensitivity 71.4%;
PDH, 62.5–72.7%
Theel et al., 2015 Antigen detection (IMMY
®
EIA with protocol
modiﬁcation)
150 Suspected PDH patients 90% of agreement with
MVista
®
EIA
Caceres et al., 2014 Antigen detection (ELISA
developed by CDC)
106  AIDS patients with
suspected histoplasmosis
Sensitivity: 86%; speciﬁcity:
94%
Babady et al., 2011 DNA detection (PCR) 797 Patients with suspected
fungal infection
Sensitivity: 73%; speciﬁcity:
100%
Tang et al., 2006 DNA detection (PCR) 76 Urine samples from
patients with
histoplasmosis and
controls
Sensitivity: 7.8%
Maubon et al., 2007 DNA detection (PCR) 40 Suspected PDH patients Sensitivity: 100% in
culture-positive
Scheel et al., 2014 DNA detection (LAMP) 16 AIDS patients with PDH and
controls
Sensitivity: 67% in
antigen-positive
AP, alkaline phosphatase; CDC, Centers for Disease Control and Prevention, Atlanta; CF, complement ﬁxation test; EIA, enzyme immunoas-
say; ELISA, enzyme-linked immunosorbent assay; HRP, Horseradish Peroxidase; ID, immunodiffusion test; LA, latex agglutination test; LAMP,
y; PC
a.
m
a
w
i
d
aloop-mediated isothermal ampliﬁcation; MAb, monoclonal antibod
histoplasmosis; RIA, radioimmunoassay; US, United States of Americ
ethod for the detection of urinary antigens in PDH, detecting
ntigens in 90% of urine and 50% of blood samples in patients
ith the disease.14 The MVista
®
Histoplasma antigen testPlease cite this article in press as: Falci DR, et al. Progressive disseminate
culture-based diagnostic tests. Braz J Infect Dis. 2016. http://dx.doi.org/10.
s based on a quantitative sandwich enzyme immunoassay
esigned for serum, plasma, urine, broncoalveolar lavage ﬂuid
nd other body ﬂuid testing.9 The manufacturer recommendsR, polymerase chain reaction test; PDH, progressive disseminated
the test not to be employed as the exclusive diagnostic tool
in patients with histoplasmosis, since cross-reactions may
occur with blastomycosis, paracoccidioidomycosis, penicillio-d histoplasmosis: a systematic review on the performance of non-
1016/j.bjid.2016.09.012
sis, sporotrichosis, coccidioidomycosis (less frequently), and
aspergillosis (rarely).9 In 2006, the test was upgraded to its sec-
ond generation eliminating false positives from the previous
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as only few laboratories in endemic countries are equipped,4  b r a z j i n f e c t d i s
method.15 Beside diagnosis, the test can also be used to mon-
itor treatment response to amphotericin B.14 Although the
MVista
®
Histoplasma antigen test has been largely studied in
HIV-infected patients, the test is only performed at the MiraV-
ista Diagnostics headquarters’ in Indiana, USA.9,11,13–15 This
is the main limitation to the use of the MVista
®
test in other
parts of the world.
The IMMY
®
ALPHA ELISA kit (IMMY,  Norman, OK) is 2-
step sandwich-type immunoenzymatic assay using polyclonal
antibodies which quantitatively detects Histoplasma antigens
in urine samples. It can be used in addition to other diagnostic
techniques such as culture, histology, and radiology. This test
was developed and validated in 2007 at the University of Utah
by Cloud and colleagues.6
The main disadvantage of the IMMY  test is the cross-
reactivity with dimorphic fungal culture ﬁltrate antigens of
C. immitis, P. brasiliensis,  and B. dermatiditis.6 Additional limi-
tations for the IMMY  test is that the test has been validated
mostly in urine samples and cannot be used for other biolog-
ical samples, such as serum or broncoalveolar lavage ﬂuid.6
A study by LeMonte and other researchers of Miravista
Diagnostics, comparing IMMY
®
and MVista
®
, found a lower
sensitivity (44%) and speciﬁcity (84%) for IMMY
®
.12 However,
a strong reaction to this study came in a letter from the deve-
lopers of IMMY
®
, denouncing technical and clinical ﬂaws.10
Theel and colleagues also compared IMMY
®
and Mvista
®
tests, showing that an overall agreement of 97.6% between the
tests. Nevertheless, IMMY
®
showed sensitivity of only 64.5% in
this study. The article points out that the MVista
®
could iden-
tify patients negative for the IMMY
®
test and both methods
present cross-reactions.8
The recent news is that IMMY  is about to launch an
ELISA kit using monoclonal antibodies against H. capsula-
tum that promise to be more  sensitive and speciﬁc than
the current assay based on polyclonal antibodies. Hamil-
ton and colleagues used monoclonal antibodies screening
cross-reactivity to dimorphic fungi with similar antigens,
as Histoplasma, Blastomyces, Sporothrix and Paracoccidioides
species.16 In 2015 Theel and colleagues updated the cut-off
points, optimizing the IMMY
®
GM ASR test (using monoclonal
antibodies) and performed a comparison with the MVista
EIA, detecting Histoplasma earlier.17 The lateral ﬂow test is
also under development by IMMY  and may allow for a real
point-of-care diagnosis for histoplasmosis, as it is available
for cryptococcosis.
Considering the HIV epidemic and the increased recog-
nition of histoplasmosis as an opportunistic disease and
cause of death in endemic countries, the US Centers for
Disease Control and Prevention (CDC) developed an in house
enzyme-linked immunosorbent assay (ELISA) for H. capsu-
latum detection. The test was initially validated in a study
conducted in Guatemala.7 This assay identiﬁes speciﬁc H.
capsulatum antigens using polyclonal antibodies, with 81%
sensitivity and 95% speciﬁcity. Cross-reactions occurred for
patients with paracoccidioidiomycosis. Similar results were
obtained in another study conducted in Colombia, with 86%
sensitivity and 94% speciﬁcity.18Please cite this article in press as: Falci DR, et al. Progressive disseminat
culture-based diagnostic tests. Braz J Infect Dis. 2016. http://dx.doi.org/10.
The detection of galactomannan (GM), a polysaccharide
that is mostly found in the cell wall of Aspergillus species, is
largely used in clinical practice for the diagnosis of invasive 6;x x x(x x):xxx–xxx
aspergillosis in neutropenic patients. As in AIDS patients
histoplasmosis if far more  common than aspergillosis, GM
detection has been suggested as a potentially helpful diag-
nostic test for histoplasmosis in this patient population.19–22
In a prospective study with 78 HIV-positive patients with sus-
pected PDH, GM testing in the urine had limited sensitivity
(12.5%) for the diagnosis of PDH (Hoffmann E, unpublished
data).
Molecular  methods
The development of polymerase chain reaction (PCR) method-
ologies for H. capsulatum has been the focus of many
laboratories for a more  rapid and sensitive detection of such
agent in tissue and body ﬂuids. In order to achieve a higher
sensitivity and speciﬁcity a number of PCR methods targeting
different regions of the H. capsulatum genome were cre-
ated, including conventional, nested, and real-time PCR.23–26
PCR methodology may be more  sensitive and speciﬁc than
immunological or serological testing, but the absence of com-
mercially available FDA-approved methods (most PCR-based
methods are homebrew technology without external vali-
dation) limit the generalization of Histoplasma PCR results.24
Based on the search and inclusion criteria, only four stud-
ies were selected when considering molecular methods.23–26
As a limitation, molecular biology methods vary in different
aspects, including DNA targets, reagents, primers, probes, and
platforms.
Babady et al. in 2001 developed and validated a real-
time PCR assay using 797 different clinical samples (not
including urine), showing sensitivity of 73% (11/15) and speci-
ﬁcity of 100% (782/782) for H. capsulatum.23 However, when
using urine samples, Tang and colleagues found a very
low sensitivity (7.8%) in 51 samples proven to be antigen-
positive by MVista
®
.26 Another study used the nested PCR
in 40 different samples from patients suspected of dis-
seminated histoplasmosis, and showed 100% sensitivity in
culture-positive samples.24 The Loop-Mediated Isothermal
Ampliﬁcation (LAMP) is a nucleic acid ampliﬁcation technique
based on the helicase activity of Bst polymerase from Bacillus
stearothermophilus.  One of the advantages of the LAMP tech-
nique relies on the fact that the Bst polymerase is cheaper
than Taq enzyme (used in PCR reactions). Also, it involves min-
imum handling time and material usage. Since results may be
interpreted using UV light, this assay may be used in resource-
limited laboratories. Although promising, LAMP presents
some weakness for diagnosis of PDH: ﬁrst, the method was
only tested in urine samples; second, sensitivity remains low
(67%); and third, the difﬁculty of rapidly and inexpensively
extracting high-quality fungal DNA remains challenging.25
Conclusions
Despite presenting a cosmopolitan distribution, the exact fre-
quency of histoplasmosis is still not known across the world,ed histoplasmosis: a systematic review on the performance of non-
1016/j.bjid.2016.09.012
prepared and able, to correctly perform the diagnosis.
According to the Global Action Fund for Fungal Infec-
tions (GAFFI), PDH is a prevalent disease in AIDS patients
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15.4 cases/1000 people/year) and present an overall lethality
s high as 45.3%. There is a major need for implementation of
 global traceability system, toward a better understanding of
he disease.
Diagnosis of disseminated histoplasmosis might be possi-
le at early stages using non-culture-based methods, reducing
ospitalization costs, and increasing patients’ survival. Sev-
ral diagnostic methods have been developed in this regard,
n particular immunologic methods for the detection of Histo-
lasma antigens in urine samples, and real-time PCR. Even
hough these infections are hyperendemic in the American
ontinent, there is an urgent need to provide countries with
ewer, faster, and sensitive techniques, in order to improve
atients’ outcomes.
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